Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA? Reply

    Research output: Contribution to journalLetter

    Original languageEnglish
    Pages (from-to)660-661
    Number of pages2
    JournalLancet Neurology
    Volume11
    Issue number8
    DOIs
    Publication statusPublished - Aug 2012

    Cite this

    @article{a4772d842eac4855985e98e5c04d455b,
    title = "Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA? Reply",
    author = "Hankey, {Graeme J.}",
    year = "2012",
    month = "8",
    doi = "10.1016/S1474-4422(12)70157-6",
    language = "English",
    volume = "11",
    pages = "660--661",
    journal = "The Lancet Neurology",
    issn = "1474-4422",
    publisher = "Academic Press",
    number = "8",

    }

    TY - JOUR

    T1 - Is rivaroxaban safer and more effective than warfarin in patients with atrial fibrillation and stroke or TIA? Reply

    AU - Hankey, Graeme J.

    PY - 2012/8

    Y1 - 2012/8

    U2 - 10.1016/S1474-4422(12)70157-6

    DO - 10.1016/S1474-4422(12)70157-6

    M3 - Letter

    VL - 11

    SP - 660

    EP - 661

    JO - The Lancet Neurology

    JF - The Lancet Neurology

    SN - 1474-4422

    IS - 8

    ER -